after radical prostatectomy, psa usually becomes undetectable within 6 weeks after surgery because the major source of psa (the prostate gland) has been removed. detectable psa following prostatectomy most likely implies residual or recurrent prostate cancer. a psa level cut point of 0.2 ng/ml or ...
However, PSA is not cancer-specific and recurrent benign prostate growth after EBRT or other minimally invasive therapies and, rarely, residual benign prostate tissue remaining in situ post-RP can generate false positives [18, 19]. Therefore, confirmation of BCR prior to treatment is crucial to ...
level less than 4 ng/dL resulting in a lower sensitivity for18F-FCH for detecting recurrent prostate cancer if the PSA was low. The authors concluded that18F-FCH PET/CT is not likely to have a significant impact on the care of prostate cancer patients with biochemical recurrence until PSA ...
Diagnostic performance of 18F-DCFPyL-PET/CT in men with biochemically recurrent prostate Cancer: results from the CONDOR Phase III, Multicenter Study. Clin Cancer Res. 2021;27(13):3674–82. Calais J, Czernin J, Fendler WP, Elashoff D, Nickols NG. Randomized prospective phase III trial of ...
Prostate-specific antigen (PSA) has revolutionised screening for and monitoring of prostate cancer (CaP). Currently, most men failing potentially curative CaP therapies develop biochemical evidence of recurrent disease (defined by detectable PSA levels) long before the onset of clinical symptoms. Androgen...
CANCER relapseRADIOTHERAPYRADIOPHARMACEUTICALSCOMPUTED tomographyRADICAL prostatectomyLOGISTIC regression analysisPROSTATE tumorsBIOCHEMISTRYAlthough local therapy for prostate cancer (PCa) is curative for some patients, 27–53% develop a biochemical recurrence (BCR), which is defined by a rise in serum prostate...
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer 来自 EBSCO 喜欢 0 阅读量: 61 作者:BA Gartrell,M Roach,A Retter,GH Sokol,GD Priore,HI Scher 摘要: Summary Background Androgen deprivation therapy (ADT) is a standard treatment ...
(68)Ga-PSMA11 PET/CT for biochemically recurrent prostate cancer: Influence of dual-time and PMT- vs SiPM-based detectors. Transl Oncol. 2022;15:101293. Plaza López PJ, Puertas E, Aguiló JJ, Suarez-Piñera M, Domenech B, Mestre-Fusco A, et al. (68)Ga-PSMA-11 PET/CT in patients...
demonstrated that in patients with biochemical recurrent prostate cancer, pooled detection rate in restaging prostate cancer was 72% [6]. Although PSMA PET-CT has improved management of pa- tients, as our experience grows with this modality, we are learning of various case...
68 Ga-RM2 PET identified recurrent prostate cancer in 23 of the 32 participants, while the simultaneous MRI scan identified findings compatible with recurrent prostate cancer in 11 of the 32 patients. PSA velocity (PSAv) values were 0.32±0.59 ng/ml/year (range: 0.04-1.9) in patients with ...